117 results
Page 2 of 6
8-K
EX-99.1
0vxpsgxj7m
27 Sep 22
Entry into a Material Definitive Agreement
8:08am
8-K
EX-99.1
5niflkewupz0
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am
DEFA14A
k1vyu2lfm i928yq0t
20 May 22
Additional proxy soliciting materials
4:31pm
8-K
EX-99.1
9pc4vq jgf4bqtwgs
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K
EX-99.1
wlpl9vqbkkbc hdv
21 Apr 22
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
7:34am
DEFA14A
sjcryq8
23 Mar 22
Additional proxy soliciting materials
7:38am
8-K
EX-99.1
spim98 mvl8
15 Mar 22
Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
8:31am
8-K
EX-99.1
a5wvzc57
1 Mar 22
Results of Operations and Financial Condition
4:17pm
8-K
EX-99.1
fzvfdts3 ipza
6 Jan 22
Zai Lab Announces NDA Acceptance of
7:44am
8-K
EX-99.1
kcvuyc
22 Dec 21
Zai Lab announces promotion of Harald Reinhart M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
4:14pm
8-K
EX-99.1
21y7 h2fj7hb7ffmk
16 Dec 21
China NMPA Approves NUZYRA® as a Category 1
7:43am
8-K
8wm47eg1micxcf
16 Dec 21
China NMPA Approves NUZYRA® as a Category 1
7:43am
8-K
EX-99.1
90p7wq037k gfkwvvbvt
3 Dec 21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
7:45am
8-K
EX-99.1
22n5g yfbmmc4skcc
22 Nov 21
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
7:40am
8-K
EX-99.3
vvh6grixsg2ivnxt5jrs
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm
8-K
EX-99.2
xxlna4kdvri km
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm